Mexico Antibody Drug Conjugates Market Size & Outlook
Mexico antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Mexico antibody drug conjugates market highlights
- The Mexico antibody drug conjugates market generated a revenue of USD 18.8 million in 2021 and is expected to reach USD 110.4 million by 2030.
- The Mexico market is expected to grow at a CAGR of 21.7% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 18.8 million |
| Market revenue in 2030 | USD 110.4 million |
| Growth rate | 21.7% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.3% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 110.4 million by 2030.
Breast cancer was the largest segment with a revenue share of 53.72% in 2021. Horizon Databook has segmented the Mexico antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
As per a 2020 report published in the US National Library of Medicine, cancer is the third most common cause of mortality in Mexico, with breast and prostate cancers being the most common types in women & men, respectively. Moreover, the prevalence of cancer has been growing over the past 20 years in the country, mainly due to lifestyle changes and growing physical inactivity.
Increasing geriatric population is expected to triple by 2050 from 2015, as per an article published in the Oxford Academic, which can further increase the prevalence of cancer. Moreover, ADC drugs such as Adcetris, used for treating relapsed or refractory Hodgkin Lymphoma, are being approved in Mexico.
As per a 2018 article published in the NCBI, although access to innovative cancer medicines has increased over the years in Mexico, it remains unequal across different insurance schemes & regions. It recommended that the Western regions of the country and particularly, the Ministry of Health Insurance Scheme, would gain from additional efforts to increase access to necessary cancer medicines.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico antibody drug conjugates market size, by application, 2018-2030 (US$M)
Mexico Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
